Root Financial Partners’s Monte Rosa Therapeutics GLUE Stock Holding History

Root Financial Partners’s Portfolio GLUE Stock Details GLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$322	Buy	+27	New	+$463	﹤0.01%	3379

Other funds holding GLUE

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Versant Venture Management San Francisco, California $109M AUM 43.78% 1-Year Est. Return

Silverarc Capital Management Boston, Massachusetts $854M AUM 179.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Aisling Capital Management New York $299M AUM 39.78% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Root Financial Partners's GLUE Position: Q3 2026 in Review

Root Financial Partners opened a new position in Monte Rosa Therapeutics (GLUE) in Q3 2026: 27 shares worth $322. The stake represents ﹤0.01% of the portfolio and ranks #3379 among its holdings.

124 funds tracked by Wall St. Rank hold GLUE as of Q3 2026.

Root Financial Partners held 27 shares of Monte Rosa Therapeutics worth $322 as of Q3 2026.
Monte Rosa Therapeutics was a new Root Financial Partners position in Q3 2026.
Monte Rosa Therapeutics made up ﹤0.01% of Root Financial Partners's portfolio in Q3 2026, its #3379 holding.
124 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q3 2026.

Based on Root Financial Partners's 13F filing for Q3 2026, filed 21 Oct 2026.